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The t(14:18) chromosomal translocation commonly found in human follicular lymphomas juxtaposes the immunoglobulin heavy chain locus with the Bcl-2 gene (Tsujimoto et al., 1985; Bakhshi et al., 1985; Cleary and Sklar, 1985) with resultant deregulation of the Bcl-2 gene and over-expression of Bcl-2 protein. Bcl-2 functions in the process of programmed cell death and has been shown to block apoptosis (Hockenbery et al., 1990) in the absence of cell proliferation (Vaux et al., 1988) . However, Bcl-2 de®cient mice exhibit normal prenatal developement although Bcl-2 expression is widespread during embryonic development (Veis et al., 1993) . This implies the existence of other gene family members also involved in the regulation of apoptosis. A number of other cellular proteins including Bax (Oltvai et al., 1993) , Bcl-x (Boise et al., 1993) , Bak (Chittenden et al., 1995; Kiefer et al., 1995) , Mcl-1 (Kozopas et al., 1993) and A1 (Lin et al., 1993) share highly conserved domains (BH-1 and BH-2; Oltvai et al., 1993) with Bcl-2. Bax is capable of forming homodimers and heterodimers with Bcl-2. The function of Bax is to accelerate apoptosis and is antagonistic to Bcl-2. Therefore the ratio of Bcl-2 to Bax regulates the apoptotic response of the cell. The Bcl-x gene produces two proteins by alternative splicing, Bcl-x S which promotes and Bcl-x L which inhibits apoptosis (Boise et al., 1993) . Recently Choi et al. (1995) described a new member of the Bcl-2 gene family, B¯-1 isolated from human fetal liver. The B¯-1 gene was originally identi®ed through comparison of homology with a novel murine gene A1 whose expression pattern was previously shown to be hematopoietic speci®c (Lin et al., 1993) .
Our laboratory previously described the independent isolation of the ®broblast growth factor 4 (FGF-4) gene by NIH3T3 transformation assay using DNA from a patient with CML leukemia (Lucas et al., 1994) . The FGF-4 gene was truncated by DNA rearrangement with a novel gene named GRS (Glasgow Rearranged Sequence) with breakpoint 30 nucleotides downstream from the translational termination codon of FGF-4. Subsequent analysis identi®ed an open reading frame within GRS. A full-length cDNA clone of the GRS sequence was then identi®ed by searching the Human Genome Sciences (HGS) database using BLASTN and TBLASTN sequence alignment algorithms (Altschul et al., 1990) . Using the 3' GRS sequence to query the HGS database, several expressed sequence tags (ESTs) were identi®ed which matched the GRS sequence exactly. A cDNA clone (unique identi®er #HG423799) corresponding to the most 5' EST was selected and sequenced to completion. The clone was obtained from a cDNA library constructed from human T cells activated with PMA and PHA.
The full-length GRS cDNA clone is 824 nucleotides in length (Figure 1a ) including 102 bp and 194 bp of 5' and 3' untranslated regions, respectively. The ®rst translational initiation signal sequence (ATG) was identi®ed beginning at nucleotide 103 of the cDNA sequence. This ATG is surrounded by sequences characteristic of a translational initiation codon (Kozak, 1995) . Two consensus polyadenylation signal sequences (AATAAA) are located in the GRS sequence between nucleotides 715 ± 720 and 781 ± 786. An 18 bp polyadenosine sequence was observed beginning 19 nucleotides downstream of the polyadenylation signal sequence.
The full-length GRS sequence was then used to query the public domain GenBank and EMBL sequence databases. The GRS sequence shows approximately 77% identity to the nucleotide sequence of a murine hematopoietic-speci®c early response gene designated A1 (Lin et al., 1993) . Furthermore, the GRS sequence shows approximately 71% identity to the murine A1 protein at the amino acid level suggesting that GRS is the human counterpart of this gene. Also, the amino acid sequence of B¯-1 and GRS dier only at two positions (amino acids #72, asparagine to threonine; #107, glutamine to histidine for B¯-1 and GRS respectively) suggesting that GRS and B¯-1 are similar or identical proteins. GRS demonstrates a high level of sequence identity with Bcl-2 and Bax, predominantly within the conserved BH-1 and BH-2 domains (Figure 1b ) further indicating that GRS is a new member of the Bcl-2 gene family.
Expression of the GRS gene at the level of mRNA (cDNA) was preliminarily analysed by searching the HGS database with the full-length GRS cDNA sequence. ESTs representing the GRS sequence appeared 22 times in the entire HGS database. ESTs representing the GRS sequence were detected from 13 independent cDNA libraries. The tissues or cells from which these libraries were generated were primarily hematopoietic in nature, with the exceptions being human fetal lung, endothelial cells (both induced and resting) and human adult liver. Tissues or cells from which libraries containing GRS ESTs were identi®ed included T cells, neutrophils, and macrophages. Due to the fact that the HGS database contains ESTs originating from over 500 cDNA libraries constructed from a wide array of human cells and tissues, these data suggest strongly that the GRS gene is expressed in adults selectively in hematopoietic tissues.
An EcoRI/XhoI fragment corresponding to the full length (824 bp) GRS cDNA was used as a hybridization probe against Northern blots containing polyadenylated RNA obtained from multiple human tissues. The results are shown in Figure 2a and b and demonstrate high levels of expression of GRS in peripheral blood and spleen, lesser expression in lung and kidney and minimal expression in other tissues. Minimal expression may re¯ect expression in a minor tissue-speci®c cell population, but more likely results from presence of co-puri®ed leukocyte RNA originating from leukocytes present in the tissue prior to RNA preparation. These results agree with data obtained from the HGS database and suggest that GRS is expressed in a tissue restricted manner, predominantly in hematopoietic tissue.
GRS cDNA was also used as a hybridization probe against a Northern blot containing mRNA isolated from human cancer cell lines. The results ( Figure 3a) show GRS is highly expressed in hematopoietic malignancies, including HL-60 promyelocytic leukemia, Raji Burkitt lymphoma and to a lesser extent K-562 chronic myeloid leukemia (CML). However, GRS is not expressed in MOLT-4, a T cell lymphoblastic leukemia. In addition, GRS is expressed at a very high level in melanoma cell line G-361. G-361 is the only non-hematopoietic cell line which expresses GRS at a Figure 1 (a) Sequence of GRS cDNA. The DNA sequence of the GRS cDNA is shown from nucleotides +1 to +824. The corresponding predicted amino acid sequence is shown below the nucleotide sequence. The predicted amino acid sequence begins with the ATG codon located from nucleotide +103 to +105 and ends with the stop codon TGA located from nucleotide +628 to +630. Both the ATG and the TGA codons are boxed. Two potential polyadenylation signal sequences are located from nucleotides +715 to +720 and +781 to +786 and are delineated by an arrow. The polyadenylation sequence, consisting of 20 adenosine residues, is located from nucleotides +805 to +824. A full-length clone of the GRS sequence was obtained by searching the Human Genome Sciences (HGS) database. The HGS database contains over 1 000 000 independent expressed sequence tags (ESTs) from over 500 independent human cDNA libraries generated using established methods (Adams et al., 1991 (Adams et al., , 1992 . The GRS cDNA clone utilized in these studies was obtained from a cDNA library prepared from activated human T cells. Human T cells isolated from peripheral blood were activated with PMA and PHA for 8 h. Total cellular RNA was then isolated from the activated cultures. The RNA was converted to cDNA and the cDNA library was constructed using a Lambda Uni-Zap XR library kit according to the manufacturer's protocol (Stratagene, La Jolla, CA). (b) Sequence identity comparison between proposed Bcl-2 family members. GRS protein shows regions of amino acid identity with both Bcl-2 and Bax proteins, especially in the BH1 (F ± DGV ± NWGRIV ± F) and BH2 (WI ± Q ± GGW ± D) domains a b high level. However, this result is not surprising since Bcl-2 is also highly expressed in melanoma (Plettenberg et al., 1995; van den Oord et al., 1994) .
Expression of GRS in cancer cell lines was further examined by RT ± PCR analysis. The results shown in Figure 3b demonstrate high levels of expression in the monocytic cell line U-937 (histiocytic lymphoma), HL-60 (promyelocytic leukemia) and Raji (Burkitt lymphoma) cells. Lower levels of expression of GRS were present in THP-1 (acute myeloid leukemia), BJAB (Burkitt lymphoma), PHA/PMA-activated Jurkat (acute T cell leukemia) cells and K-562 erythroleukemia (CML blast crisis). The GRS transcript size is reduced in K-562 cells. We do not yet know whether this results from an alternative splicing event or a deletion within GRS in these cells. HeLa (epitheloid carcinoma), Tera-2 (embryonal carcinoma) and nonactivated Jurkat cells in contrast do not appear to express GRS. The additional low level of expression in thymus suggests expression is limited to only a subpopulation of T cells. Lack of expression in T cells prior to activation and low level expression in K-562 cells, which have been placed within the hematopoietic lineage as multipotent stem cells (Fraser and Berridge, 1987; Leary et al., 1987) , suggests further that GRS may not be expressed in early-lineage cells and that expression is limited within the hematopoietic compartment to more dierentiated cell types. However, whether GRS mimics Bcl-2 and is also expressed in the earliest pluripotent stem cells (Veis et al., 1993) is as yet unknown.
To determine the precise chromosomal location of the GRS gene we did¯uorescence in situ hybridization (FISH) analysis using the nick-translated GRS gene probe and normal human metaphase chromosome spreads. Digitized images of ten metaphases were recorded, each of which had a doublet signal characteristic of genuine hybridization on both homologues of chromosome #15 (Figure 4 ). Consistent doublet signal was not detected on any other chromosome. Using high-resolution imaging software, the band position was assigned based on the location of gene signal on 14 individual chromosomes counterstained with DAPI using conditions which enhanced gbands. This analysis indicated that the GRS gene is positioned within bands 15q24-25 (Figure 4) . The position of GRS at 15q24-25 places the gene adjacent to, but not within, the t(15;17) region of translocation associated with acute promyelocytic leukemia (De The et al., 1990) . However, it is interesting that GRS is located at the position of a chromosomal breakpoint t(X:15)(q23;25) described in a Fanconi anemia (KokaljVokac et al., 1991), a congenital disease associated with high incidence of acute leukemia and areas of skin hyperpigmentation.
GRS was originally isolated by NIH3T3 focus formation assay using DNA obtained from a patient with chronic myeloid leukemia. The FGF-4/GRS rearrangement was detectable by Southern analysis in primary and secondary transformed foci, but not in the original CML DNA. Additionally, PCR analysis using primers spanning the FGF-4/GRS breakpoint did not detect the rearrangement in the original DNA (Lucas et al., 1994) . We have now performed Southern analysis on the CML DNA sample using full-length GRS cDNA as a hybridization probe. The restriction enzyme (EcoRI, HindIII, KpnI, XbaI) pro®le for GRS in the CML DNA appears identical to that of normal human DNA (data not shown), suggesting that the FGF-4/GRS rearrangement resulted from a transfection artifact. That a Bcl-2 gene family member (GRS) has been found rearranged with a growth factor/ oncogene (FGF-4) after transformation with DNA from a CML patient is nevertheless intriguing. This DNA rearrangement is particularly interesting since FGF-4 is located at a chromosomal site (11q13) shown to be involved in complex BCR/ABL translocations in CML (Morris et al., 1996) . An alternative possibility is that this rearrangement existed in a minor population of cells which did not represent the primary leukemic clone. In this respect, it is of further interest that FGF-4 has been shown to be capable of increasing the growth rate of stromal cells and consequently to extend the life of hematopoietic cells in long-term bone marrow cultures (Quito et al., 1996) . However, it is nevertheless surprising that the FGF-4/GRS rearrangement is not detectable by PCR analysis.
While the FGF-4/GRS rearrangement cannot be detected in the original patient DNA, mutational changes within the DNA sequence of GRS can be detected, including a single nucleotide insertion at position 608 on the cDNA sequence (below in bold) and nucleotide substitutions at positions 606 and 610 (below underlined), resulting in sequence change 5'-ATGCTATCTCTCC-3' to 5'-ATGCTCTTCTGTCC. The mutant sequence is detectable in the original lambda clone harboring the 3' exon of GRS. In addition, direct sequencing of the PCR product generated by PCR ampli®cation of the cloned 3' exon from the original patient DNA, and sequencing of the P]dCTP-labeled probe comprising the full length GRS cDNA. Lanes 1 ± 8; HL-60 promyelocytic leukemia, HeLa S3 epidermoid carcinoma, K-562 chronic myeloid leukemia, MOLT-4 lymphoblastic T-cell leukemia, Raji Burkitt's lymphoma, SW480 colorectal adenocarcinoma, A549 lung carcinoma, G-361 melanoma. (b) RT ± PCR analysis. Lanes 1 ± 11; HL-60, Raji, U-937, THP-1, K-562, Jurkat, Jurkat PHA/PMA, BJAB, NTera-2, HeLa S3, Negative control (Blank). Slight over-exposure of the GRS samples was necessary to show the shorter transcript present only in the K-562 cell line which supports the Northern blot analysis ®ndings. Total RNA was isolated from cell lines using TRIzol Reagent (GIBCO BRL, Gaithersburg, MD) and processed according to the manufacturer's protocol. All reagents used for RT ± PCR were obtained from GIBCO BRL (Gaithersburg, MD) unless otherwise indicated. 0.75 mg of total RNA was used for ®rst strand cDNA synthesis. RNA and 100 pmol of random hexamer primers were denatured at 708C for 10 min and quick chilled to 48C. First strand cDNA synthesis using 100 U SuperscriptII reverse transcriptase was performed in a 20 mL reaction containing RNA/hexamer mixture, 16synthesis buer, 10 mM DTT and 250 mM each dNTP. Synthesis proceeded at 258C for 5 min, 378C for 20 min, 428C for 20 min, sequential temperature ramp from 428C to 508C for 15 min, and 908C for 5 min in a Perkin-Elmer 9600 thermocycler. Completed ®rst strand cDNA reactions were treated with 1.25 U RNaseH (Amersham Life Science, Arlington Heights, IL) at 378C for 30 min. For PCR ampli®cation 2 mL of the cDNA were included in a 25 mL reaction containing 20 mM Tris, 50 mM KCl, 0.625 U Taq DNA polymerase, 10 pmol each of the upstream and downstream oligonucleotide primer, 125 mM each dNTP and 66 nM [a 32 P]dCTP. The oligonucleotide primers used for GRS ampli®cation were 5'-CAG GCT GGC TCA GGA CTA TCT GC-3' (forward) and 5'-TGT CCT TTC TGG TCA A-CA GTA TTG C-3' (reverse) and for GAPDH, 5'-TCT ACT GGC GCT GCC AAG GCT GT-3' (forward) and 5'-GCC ATG AGG TCC ACC ACC CTG T-3' (reverse). Final MgCl 2 concentrations for GRS and GAPDH PCR reactions were 3 mM and 1.5 mM, respectively. Ampli®cation pro®les consisted of an initial ®ve cycles using 978C denaturation for 1 min, 558C annealing for 1 min, and 748C extension for 1 min. Remaining cycles proceeded as 948C for 1 min, 578C for 1 min and 748C for 1 min. An extension of 748C for 5 min was added after the ®nal ampli®cation cycle and reactions stored at 48C until analysed. Optimal ampli®cation cycle numbers for GRS and GAPDH products were determined by analysing cycle numbers 15 through 35 in two cycle increments until an ampli®cation plateau was observed (data not shown). GRS and GAPDH were ampli®ed for 27 and 22 cycles, respectively to maintain each product in the linear range of their ampli®cation curve (data not shown). PCR products and a 100 bp DNA ladder (GIBCO BRL, Gaithersburg, MD) were resolved through a 2% TAE agarose gel containing ethidium bromide, visualized under u.v. illumination, electroblotted on a Bio-Rad Semi-Dry Electroblotter SD and exposed to HyperFilm MP at room temperature GRS genomic PAC DNA was nick-translated using digoxigenindUTP (Boehringer Mannheim). Fluorescence in situ hybridization was performed as described previously (Johnson et al., 1991) . Chromosome spreads were counter-stained with DAPI and color digital images containing both DAPI bands and gene signal were recorded using a triple-band pass ®lter set (Chroma Technology, Inc, Brattleboro, VT), a charged coupled-device camera (Photometrics, Inc, Tucson, AZ) and variable excitation wavelength ®lters. Images of metaphase spreads were stored and analysed using the ISEE software package (Inovision Corp, Durham, NC). Individual chromosomes containing doublet gene signals were evaluated and gene signal location was assigned based on the DAPI banding pattern cloned PCR product con®rms the mutational changes, while the PCR product generated from a control cell line (colon carcinoma COLO 320) remains normal (data not shown). The T nucleotide insertion predicts an altered reading frame, changing the sequence of the last seven amino acids of the protein and extending the open reading frame for an additional 38 amino acids (data not shown). How this change might alter function of GRS is unclear. However, the carboxyterminal 22 amino acids of Bcl-2 are known to be essential for membrane targeting of the protein (Nguyen et al., 1993) . If this region of GRS has a similar function, then mutation would be predicted to aect membrane targeting of GRS.
An alternative explanation for the mutations observed in the leukemia DNA is that the genomic sequence obtained results from sequence polymorphism or alternatively is part of a non-processed pseudogene. Sequence of upstream exons of GRS from the leukemic DNA is not yet available for comparison, and presently we cannot determine which of the above explanations is correct. Analysis of the sequence of GRS in other leukemic and normal samples is now necessary in order to determine the polymorphic nature of this locus and concomitant analysis of the genomic structure of GRS should allow identi®cation of a GRS pseudogene.
